Business Of Biotech BoB@JPM: Tom Chalberg, Ph.D., Genascence
Feb 24, 2025
In a captivating discussion, Tom Chalberg, Founder and CEO of Genascence, shares his journey from academia to leading innovations in gene therapy. He dives into the evolution of gene treatment, focusing on addressing widespread conditions like osteoarthritis. The conversation reveals the complexities of navigating regulatory landscapes for common vs. rare diseases. Chalberg also discusses the exciting breakthroughs in gene therapy and the strategic partnerships critical for funding in today’s biotech climate, painting a vivid picture of the industry's future.
AI Snips
Chapters
Transcript
Episode notes
Genetic Medicine Interest
- Dr. Chalberg's interest in genetic medicine stemmed from the human genome sequencing.
- This led him to pursue cancer biology, genetics, and ophthalmology, focusing on gene therapy applications.
Avalanche Founding
- Dr. Chalberg co-founded Avalanche Biotech in 2008 during the financial crisis.
- Raising capital was challenging, but the downturn allowed for focused innovation without intense competition.
Innovation in Down Cycles
- Down cycles in biotech offer unique opportunities for innovation.
- Reduced competition allows entrepreneurs to explore future possibilities and gain a head start.